Most cancers are detected when patients present with symptoms, and at that point the disease is usually quite advanced and often not curable. Therefore, new biomarkers are needed for detection and therapy. The recent success of using monoclonal antibodies against nonprotein gangliosides for the treatment of high-risk neuroblastoma provides an incentive to search for new glycan-targeted immunotherapies for cancer using markers found through glycomic analysis as targets. Since more than 85% of cell surface components are glycosylated, glycomic analysis is useful to probe systematically the cancer cell surface, in search for novel glycoproteins and glycolipids. Furthermore, cancer cells tend to dedifferentiate and express many oncofetoproteins, since human embryonic stem cells (ESCs) are derived from epiblast of embryo, representing the early stage of normal embryonic development before gastrulation. Unique ESC surface markers are likely to be found in cancer cells, but not in normal mature tissues. Moreover, stem cells and cancer cells share several common features in related regulatory mechanisms and signaling pathways. Thus, identification of the cancer stem cells in cancer and definition of the glycoproteomic changes that accompany their transformation are important for the development of strategies for early detection and treatment of cancer.
PointnerR., ConradF., SchwabG.. Tumor markers in the upper intestinal tract–stomach and pancreas.Wien Klin Wochenschr1989; 101: 482–4.
2.
GoldenbergD.M., NevilleA.M., CarterA.C.. CEA (carcinoembryonic antigen): its role as a marker in the management of cancer.J Cancer Res Clin Oncol1981; 101: 239–42.
3.
HanadaH., MugiiS., TakeokaK.. Early detection of colorectal cancer metastasis and relapse by recognizing nonspecific cross-reacting antigen 2 in commercial carcinoembryonic antigen assays.Clin Chem2009; 55: 1747–8.
4.
OsmanN., O'LearyN., MulcahyE.. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre.Ir Med J2008; 101: 245–7.
5.
SuhK.S., ParkS.W., CastroA.. Ovarian cancer biomarkers for molecular biosensors and translational medicine.Expert Rev Mol Diagn2010; 10: 1069–83.
6.
FritscheH.A., BastR.C.. CA 125 in ovarian cancer: advances and controversy.Clin Chem1998; 44: 1379–80.
7.
HuangC.S., LinC.H., LuY.S., ShenC.Y.. Unique features of breast cancer in Asian women–breast cancer in Taiwan as an example.J Steroid Biochem Mol Biol2010; 118: 300–3.
8.
LangH.C., WuS.L.. Lifetime costs of the top five cancers in Taiwan.Eur J Health Econ2012; 13: 347–53.
9.
TsoiD.T., InoueM., KellyC.M., VermaS., PritchardK.. Cost-effectiveness analysis of oncotype DX-guided treatment in early breast cancer.J Clin Oncol2009; 27: e11536.
10.
KlangS.H., HammermanA., LiebermannN., EfratN., DoberneJ., HornbergerJ.. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed healthcare organization.Value Health2010; 13: 381–7.
11.
HarrisL., FritscheH., MennelR.. Amer Soc of Clin Oncol. Update of Recommendations for the Use of Tumor Markers in Breast Cancer.JCO2007; 25: 5287–312.
12.
CardosoF., Van't VeerL., RutgersE., LoiS., MookS., Piccart-GebhartM.J.. Clinical application of the 70-gene profile: the MIND-ACT trial.J Clin Oncol2008; 26: 729–35.
13.
LiuR., WangX., ChenG.Y.. The prognostic role of a gene signature from tumorigenic breast-cancer cells.N Engl J Med2007; 356: 217–26.
14.
DubeD.H., BertozziC.R.. Glycans in cancer and inflammation-potential for therapeutics and diagnostics.Nat Rev Drug Discov2005; 4: 477–88.
15.
HansonS.R., HsuT.L., WeerapanaE.. Tailored glycoproteomics and glycan site mapping using saccharide-selective bioorthogonal probes.J Am Chem Soc2007; 129: 7266–7.
16.
LiangY.J., KuoH.H., LinC.H.. Switching of the core structures of glycosphingolipids from globo- and lacto- to ganglio-series upon human embryonic stem cell differentiation.Proc Natl Acad Sci U S A2010; 107: 22564–9.
17.
LiangY.J., YangB.C., ChenJ.M.. Changes in glycosphingolipid composition during differentiation of human embryonic stem cells to ectodermal or endodermal lineages.Stem Cells2011; 29: 1995–2004.
18.
YuA.L., GilmanA.L., OzkaynakM.F.. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma.N Engl J Med2010; 363: 1324–34.
19.
FujitaniN., TakegawaY., IshibashiY.. Qualitative and quantitative cellular glycomics of glycosphingolipids based on rho-dococcal endoglycosylceramidase-assisted glycan cleavage, glycoblotting-assisted sample preparation, and matrix-assisted laser desorption ionization tandem time-of-flight mass spectrometry analysis.J Biol Chem2011; 286: 41669–79.
20.
ChangW.W., LeeC.H., LeeP.. Expression of Globo H and SSEA3 in breast cancer stem cells and the involvement of fu-cosyl transferases 1 and 2 in Globo H synthesis.Proc Natl Acad Sci U S A2008; 105: 11667–72.
21.
BremerE.G., LeveryS.B., SonninoS.. Characterization of a glycosphingolipid antigen defined by the monoclonal antibody MBr1 expressed in normal and neoplastic epithelial cells of human mammary gland.J Biol Chem1984; 259: 14773–7.
22.
Akira Inoue, Toshihiro Nukiwa.Gene mutations in lung cancer: promising predictive factors for the success of molecular therapy.PLoS Med2005; 2: e13.
23.
ReyaT., MorrisonS.J., ClarkeM.F., WeissmanI.L.. Stem cells, cancer, and cancer stem cells.Nature2001; 414: 105–11.
24.
ChoH.C., LaiC.Y., ShaoL.E., YuJ.. Identification of tumorigenic cells in Kras (G12D)-induced lung adenocarcinoma.Cancer Res2011; 71: 7250–8.
25.
PerlA.K., WertS.E., LoudyD.E., ShanZ., BlairP.A., WhitsettJ.A.. Conditional recombination reveals distinct subsets of epithelial cells in trachea, bronchi, and alveoli.Am J Respir Cell Mol Biol2005; 33: 455–62.
26.
KelberJ.A., PanopoulosA.D., ShaniG.. Blockade of Cripto binding to cell surface GRP78 inhibits oncogenic Cripto signaling via MAPK/PI3K and Smad2/3 pathways.Oncogene2009; 28: 2324–36.
27.
MiharadaK., KarlssonG., RehnM.. Cripto regulates hematopoietic stem cells as a hypoxic-niche-related factor through cell surface receptor GRP78.Cell Stem Cell2011; 9: 330–44.
28.
BertoliniG., RozL., PeregoP.. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment.Proc Natl Acad Sci U S A2009; 106: 16281–6.
29.
EramoA., LottiF., SetteG.. Identification and expansion of the tumorigenic lung cancer stem cell population.Cell Death Differ2008; 15: 504–14.
30.
CreaF., FornaroL., MasiG., FalconeA., DanesiR., FarrarW.. Faithful markers of circulating cancer stem cells: is CD133 sufficient for validation in clinics?J Clin Oncol2011; 29: 3487–8; author reply 3488–90.
31.
GreenC.L., LokenM., BuckD., DeegH.J.. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) and acute myelogeneous leukemia (AML).Leukemia2000; 14: 770–2.
32.
MiragliaS., GodfreyW., YinA.H.. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning.Blood1997; 90: 5013–21.
33.
O'BrienC.A., PollettA., GallingerS., DickJ.E.. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice.Nature2007; 445: 106–10.
34.
TodaroM., AleaM.P., Di StefanoA.B.. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4.Cell Stem Cell2007; 1: 389–402.
35.
KemperK., SprickM.R., de BreeM.. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation.Cancer Res2010; 70: 719–29.
36.
CurtisS.J., SinkeviciusK.W., LiD.. Primary tumor genotype is an important determinant in identification of lung cancer propagating cells.Cell Stem Cell2010; 7: 127–33.
37.
McQualterJ.L., BrouardN., WilliamsB.. Endogenous fibroblastic progenitor cells in the adult mouse lung are highly enriched in the sca-1 positive cell fraction.Stem Cells2009; 27: 623–33.
